270 related articles for article (PubMed ID: 26028965)
1. Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.
Cascavilla N; De Stefano V; Pane F; Pancrazzi A; Iurlo A; Gobbi M; Palandri F; Specchia G; Liberati AM; D'Adda M; Gaidano G; Fjerza R; Achenbach H; Smith J; Wilde P; Vannucchi AM
Drug Des Devel Ther; 2015; 9():2687-94. PubMed ID: 26028965
[TBL] [Abstract][Full Text] [Related]
2. Anagrelide and Mutational Status in Essential Thrombocythemia.
Iurlo A; Cattaneo D; Orofino N; Bucelli C; Fabris S; Cortelezzi A
BioDrugs; 2016 Jun; 30(3):219-23. PubMed ID: 27041108
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
Mela Osorio MJ; Ferrari L; Goette NP; Gutierrez MI; Glembotsky AC; Maldonado AC; Lev PR; Alvarez C; Korin L; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2016 Apr; 96(4):435-42. PubMed ID: 26119186
[TBL] [Abstract][Full Text] [Related]
4. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.
Larsen TS; Pallisgaard N; de Stricker K; Møller MB; Hasselbalch HC
Hematology; 2009 Feb; 14(1):11-5. PubMed ID: 19154659
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
Kwiatkowski J; Kuliszkiewicz-Janus M; Rymer W; Jaźwiec B; Małecki R
Pharmacology; 2021; 106(5-6):316-322. PubMed ID: 33691325
[TBL] [Abstract][Full Text] [Related]
6. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
7. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
Iványi JL; Marton É; Plander M; Szendrei T
Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
[TBL] [Abstract][Full Text] [Related]
8. Anagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologists.
Reilly JT
Hematology; 2009 Feb; 14(1):1-10. PubMed ID: 19154658
[TBL] [Abstract][Full Text] [Related]
9. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
10. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
[TBL] [Abstract][Full Text] [Related]
11. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.
Antonioli E; Guglielmelli P; Poli G; Bogani C; Pancrazzi A; Longo G; Ponziani V; Tozzi L; Pieri L; Santini V; Bosi A; Vannucchi AM;
Haematologica; 2008 Jan; 93(1):41-8. PubMed ID: 18166784
[TBL] [Abstract][Full Text] [Related]
12. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
13. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
[TBL] [Abstract][Full Text] [Related]
15. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
16. Essential thrombocythemia: scientific advances and current practice.
Tefferi A
Curr Opin Hematol; 2006 Mar; 13(2):93-8. PubMed ID: 16456375
[TBL] [Abstract][Full Text] [Related]
17. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.
Muendlein A; Gasser K; Kinz E; Stark N; Leiherer A; Rein P; Saely CH; Grallert H; Peters A; Drexel H; Lang AH
Am J Hematol; 2014 Mar; 89(3):295-301. PubMed ID: 24265174
[TBL] [Abstract][Full Text] [Related]
19. JAK2+ Essential Thrombocythemia in a Young Girl With Budd-Chiari Syndrome: Diagnostic and Therapeutic Considerations When Adult Disease Strikes the Young.
Wigton JC; Tersak JM
J Pediatr Hematol Oncol; 2016 Jan; 38(1):70-3. PubMed ID: 26523382
[TBL] [Abstract][Full Text] [Related]
20. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
